title: GI cancers in 2010: New standards and a predictive biomarker for adjuvant therapy.
abstract: Randomized phase III trials have established new standards of care for advanced biliary cancer, HER2-positive advanced gastric or gastro-esophageal junction cancer, and preliminarily, for metastatic pancreatic cancer. There is now a validated predictive biomarker to guide use of adjuvant chemotherapy in patients with stage II colon cancer.
authors.affiliation: Section of Hematology-Oncology, Department of Medicine, Comprehensive Cancer Center, University of Chicago, 5841 South Maryland Avenue, Chicago, IL 60637-1470, USA.
authors.forename: Manish R
authors.initials: MR
authors.lastname: Sharma
authors.forename: Richard L
authors.initials: RL
authors.lastname: Schilsky
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics; D017024:Chemotherapy, Adjuvant; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D059039:Standard of Care; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor